The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.
Identifieur interne : 001411 ( PubMed/Corpus ); précédent : 001410; suivant : 001412The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.
Auteurs : Léon C L. Van Kempen ; Margaret Redpath ; Mounib Elchebly ; Kathleen Oros Klein ; Andreas I. Papadakis ; James S. Wilmott ; Richard A. Scolyer ; Per-Henrik Edqvist ; Fredrik Pontén ; Dirk Schadendorf ; Anke F. Van Rijk ; Stefan Michiels ; Anne Dumay ; Anne Helbling-Leclerc ; Philippe Dessen ; Jasper Wouters ; Marguerite Stass ; Celia M T. Greenwood ; Ghanem E. Ghanem ; Joost Van Den Oord ; Jean Feunteun ; Alan SpatzSource :
- Science translational medicine [ 1946-6242 ] ; 2016.
Abstract
Male gender is independently and significantly associated with poor prognosis in melanoma of all clinical stages. The biological underpinnings of this sex difference remain largely unknown, but we hypothesized that gene expression from gonosomes (sex chromosomes) might play an important role. We demonstrate that loss of the inactivated X chromosome in melanomas arising in females is strongly associated with poor distant metastasis-free survival, suggesting a dosage benefit from two X chromosomes. The gonosomal protein phosphatase 2 regulatory subunit B, beta (PPP2R3B) gene is located on the pseudoautosomal region (PAR) of the X chromosome in females and the Y chromosome in males. We observed that, despite its location on the PAR that predicts equal dosage across genders, PPP2R3B expression was lower in males than in females and was independently correlated with poor clinical outcome. PPP2R3B codes for the PR70 protein, a regulatory substrate-recognizing subunit of protein phosphatase 2A. PR70 decreased melanoma growth by negatively interfering with DNA replication and cell cycle progression through its role in stabilizing the cell division cycle 6 (CDC6)-chromatin licensing and DNA replication factor 1 (CDT1) interaction, which delays the firing of origins of DNA replication. Hence, PR70 functionally behaves as an X-linked tumor suppressor gene.
DOI: 10.1126/scitranslmed.aai9188
PubMed: 27974665
Links to Exploration step
pubmed:27974665Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.</title><author><name sortKey="Van Kempen, Leon C L" sort="Van Kempen, Leon C L" uniqKey="Van Kempen L" first="Léon C L" last="Van Kempen">Léon C L. Van Kempen</name><affiliation><nlm:affiliation>Department of Pathology, McGill University, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Redpath, Margaret" sort="Redpath, Margaret" uniqKey="Redpath M" first="Margaret" last="Redpath">Margaret Redpath</name><affiliation><nlm:affiliation>Department of Pathology, McGill University, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Elchebly, Mounib" sort="Elchebly, Mounib" uniqKey="Elchebly M" first="Mounib" last="Elchebly">Mounib Elchebly</name><affiliation><nlm:affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Klein, Kathleen Oros" sort="Klein, Kathleen Oros" uniqKey="Klein K" first="Kathleen Oros" last="Klein">Kathleen Oros Klein</name><affiliation><nlm:affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Papadakis, Andreas I" sort="Papadakis, Andreas I" uniqKey="Papadakis A" first="Andreas I" last="Papadakis">Andreas I. Papadakis</name><affiliation><nlm:affiliation>Department of Pathology, McGill University, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Wilmott, James S" sort="Wilmott, James S" uniqKey="Wilmott J" first="James S" last="Wilmott">James S. Wilmott</name><affiliation><nlm:affiliation>Melanoma Institute Australia, Royal Prince Alfred Hospital, and University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Scolyer, Richard A" sort="Scolyer, Richard A" uniqKey="Scolyer R" first="Richard A" last="Scolyer">Richard A. Scolyer</name><affiliation><nlm:affiliation>Melanoma Institute Australia, Royal Prince Alfred Hospital, and University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Edqvist, Per Henrik" sort="Edqvist, Per Henrik" uniqKey="Edqvist P" first="Per-Henrik" last="Edqvist">Per-Henrik Edqvist</name><affiliation><nlm:affiliation>Department of Immunology, Genetics and Pathology, and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Ponten, Fredrik" sort="Ponten, Fredrik" uniqKey="Ponten F" first="Fredrik" last="Pontén">Fredrik Pontén</name><affiliation><nlm:affiliation>Department of Immunology, Genetics and Pathology, and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name><affiliation><nlm:affiliation>Department of Dermatology, University Hospital Essen, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Van Rijk, Anke F" sort="Van Rijk, Anke F" uniqKey="Van Rijk A" first="Anke F" last="Van Rijk">Anke F. Van Rijk</name><affiliation><nlm:affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation><nlm:affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dumay, Anne" sort="Dumay, Anne" uniqKey="Dumay A" first="Anne" last="Dumay">Anne Dumay</name><affiliation><nlm:affiliation>Centre de Recherche sur l'Inflammation, INSERM, UMR S 1149, Labex Inflamex, Université Paris-Diderot Sorbonne Paris-Cité, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Helbling Leclerc, Anne" sort="Helbling Leclerc, Anne" uniqKey="Helbling Leclerc A" first="Anne" last="Helbling-Leclerc">Anne Helbling-Leclerc</name><affiliation><nlm:affiliation>CNRS, UMR 8200, Université Paris-Sud, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dessen, Philippe" sort="Dessen, Philippe" uniqKey="Dessen P" first="Philippe" last="Dessen">Philippe Dessen</name><affiliation><nlm:affiliation>Hématopoïèse normale et pathologique, INSERM UMR 1170, Université Paris-Sud, Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Wouters, Jasper" sort="Wouters, Jasper" uniqKey="Wouters J" first="Jasper" last="Wouters">Jasper Wouters</name><affiliation><nlm:affiliation>Laboratory of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Stass, Marguerite" sort="Stass, Marguerite" uniqKey="Stass M" first="Marguerite" last="Stass">Marguerite Stass</name><affiliation><nlm:affiliation>Department of Surgical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Greenwood, Celia M T" sort="Greenwood, Celia M T" uniqKey="Greenwood C" first="Celia M T" last="Greenwood">Celia M T. Greenwood</name><affiliation><nlm:affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ghanem, Ghanem E" sort="Ghanem, Ghanem E" uniqKey="Ghanem G" first="Ghanem E" last="Ghanem">Ghanem E. Ghanem</name><affiliation><nlm:affiliation>Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Van Den Oord, Joost" sort="Van Den Oord, Joost" uniqKey="Van Den Oord J" first="Joost" last="Van Den Oord">Joost Van Den Oord</name><affiliation><nlm:affiliation>Laboratory of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Feunteun, Jean" sort="Feunteun, Jean" uniqKey="Feunteun J" first="Jean" last="Feunteun">Jean Feunteun</name><affiliation><nlm:affiliation>CNRS UMR 8200, Universite Paris-Sud, Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Spatz, Alan" sort="Spatz, Alan" uniqKey="Spatz A" first="Alan" last="Spatz">Alan Spatz</name><affiliation><nlm:affiliation>Department of Pathology, McGill University, Montreal, Quebec, Canada. alan.spatz@mcgill.ca.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27974665</idno><idno type="pmid">27974665</idno><idno type="doi">10.1126/scitranslmed.aai9188</idno><idno type="wicri:Area/PubMed/Corpus">001411</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001411</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.</title><author><name sortKey="Van Kempen, Leon C L" sort="Van Kempen, Leon C L" uniqKey="Van Kempen L" first="Léon C L" last="Van Kempen">Léon C L. Van Kempen</name><affiliation><nlm:affiliation>Department of Pathology, McGill University, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Redpath, Margaret" sort="Redpath, Margaret" uniqKey="Redpath M" first="Margaret" last="Redpath">Margaret Redpath</name><affiliation><nlm:affiliation>Department of Pathology, McGill University, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Elchebly, Mounib" sort="Elchebly, Mounib" uniqKey="Elchebly M" first="Mounib" last="Elchebly">Mounib Elchebly</name><affiliation><nlm:affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Klein, Kathleen Oros" sort="Klein, Kathleen Oros" uniqKey="Klein K" first="Kathleen Oros" last="Klein">Kathleen Oros Klein</name><affiliation><nlm:affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Papadakis, Andreas I" sort="Papadakis, Andreas I" uniqKey="Papadakis A" first="Andreas I" last="Papadakis">Andreas I. Papadakis</name><affiliation><nlm:affiliation>Department of Pathology, McGill University, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Wilmott, James S" sort="Wilmott, James S" uniqKey="Wilmott J" first="James S" last="Wilmott">James S. Wilmott</name><affiliation><nlm:affiliation>Melanoma Institute Australia, Royal Prince Alfred Hospital, and University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Scolyer, Richard A" sort="Scolyer, Richard A" uniqKey="Scolyer R" first="Richard A" last="Scolyer">Richard A. Scolyer</name><affiliation><nlm:affiliation>Melanoma Institute Australia, Royal Prince Alfred Hospital, and University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Edqvist, Per Henrik" sort="Edqvist, Per Henrik" uniqKey="Edqvist P" first="Per-Henrik" last="Edqvist">Per-Henrik Edqvist</name><affiliation><nlm:affiliation>Department of Immunology, Genetics and Pathology, and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Ponten, Fredrik" sort="Ponten, Fredrik" uniqKey="Ponten F" first="Fredrik" last="Pontén">Fredrik Pontén</name><affiliation><nlm:affiliation>Department of Immunology, Genetics and Pathology, and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name><affiliation><nlm:affiliation>Department of Dermatology, University Hospital Essen, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Van Rijk, Anke F" sort="Van Rijk, Anke F" uniqKey="Van Rijk A" first="Anke F" last="Van Rijk">Anke F. Van Rijk</name><affiliation><nlm:affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation><nlm:affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dumay, Anne" sort="Dumay, Anne" uniqKey="Dumay A" first="Anne" last="Dumay">Anne Dumay</name><affiliation><nlm:affiliation>Centre de Recherche sur l'Inflammation, INSERM, UMR S 1149, Labex Inflamex, Université Paris-Diderot Sorbonne Paris-Cité, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Helbling Leclerc, Anne" sort="Helbling Leclerc, Anne" uniqKey="Helbling Leclerc A" first="Anne" last="Helbling-Leclerc">Anne Helbling-Leclerc</name><affiliation><nlm:affiliation>CNRS, UMR 8200, Université Paris-Sud, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dessen, Philippe" sort="Dessen, Philippe" uniqKey="Dessen P" first="Philippe" last="Dessen">Philippe Dessen</name><affiliation><nlm:affiliation>Hématopoïèse normale et pathologique, INSERM UMR 1170, Université Paris-Sud, Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Wouters, Jasper" sort="Wouters, Jasper" uniqKey="Wouters J" first="Jasper" last="Wouters">Jasper Wouters</name><affiliation><nlm:affiliation>Laboratory of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Stass, Marguerite" sort="Stass, Marguerite" uniqKey="Stass M" first="Marguerite" last="Stass">Marguerite Stass</name><affiliation><nlm:affiliation>Department of Surgical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Greenwood, Celia M T" sort="Greenwood, Celia M T" uniqKey="Greenwood C" first="Celia M T" last="Greenwood">Celia M T. Greenwood</name><affiliation><nlm:affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ghanem, Ghanem E" sort="Ghanem, Ghanem E" uniqKey="Ghanem G" first="Ghanem E" last="Ghanem">Ghanem E. Ghanem</name><affiliation><nlm:affiliation>Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Van Den Oord, Joost" sort="Van Den Oord, Joost" uniqKey="Van Den Oord J" first="Joost" last="Van Den Oord">Joost Van Den Oord</name><affiliation><nlm:affiliation>Laboratory of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Feunteun, Jean" sort="Feunteun, Jean" uniqKey="Feunteun J" first="Jean" last="Feunteun">Jean Feunteun</name><affiliation><nlm:affiliation>CNRS UMR 8200, Universite Paris-Sud, Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Spatz, Alan" sort="Spatz, Alan" uniqKey="Spatz A" first="Alan" last="Spatz">Alan Spatz</name><affiliation><nlm:affiliation>Department of Pathology, McGill University, Montreal, Quebec, Canada. alan.spatz@mcgill.ca.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Science translational medicine</title><idno type="eISSN">1946-6242</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Male gender is independently and significantly associated with poor prognosis in melanoma of all clinical stages. The biological underpinnings of this sex difference remain largely unknown, but we hypothesized that gene expression from gonosomes (sex chromosomes) might play an important role. We demonstrate that loss of the inactivated X chromosome in melanomas arising in females is strongly associated with poor distant metastasis-free survival, suggesting a dosage benefit from two X chromosomes. The gonosomal protein phosphatase 2 regulatory subunit B, beta (PPP2R3B) gene is located on the pseudoautosomal region (PAR) of the X chromosome in females and the Y chromosome in males. We observed that, despite its location on the PAR that predicts equal dosage across genders, PPP2R3B expression was lower in males than in females and was independently correlated with poor clinical outcome. PPP2R3B codes for the PR70 protein, a regulatory substrate-recognizing subunit of protein phosphatase 2A. PR70 decreased melanoma growth by negatively interfering with DNA replication and cell cycle progression through its role in stabilizing the cell division cycle 6 (CDC6)-chromatin licensing and DNA replication factor 1 (CDT1) interaction, which delays the firing of origins of DNA replication. Hence, PR70 functionally behaves as an X-linked tumor suppressor gene.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27974665</PMID><DateCreated><Year>2016</Year><Month>12</Month><Day>15</Day></DateCreated><DateRevised><Year>2016</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>369</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.</ArticleTitle><Pagination><MedlinePgn>369ra177</MedlinePgn></Pagination><Abstract><AbstractText>Male gender is independently and significantly associated with poor prognosis in melanoma of all clinical stages. The biological underpinnings of this sex difference remain largely unknown, but we hypothesized that gene expression from gonosomes (sex chromosomes) might play an important role. We demonstrate that loss of the inactivated X chromosome in melanomas arising in females is strongly associated with poor distant metastasis-free survival, suggesting a dosage benefit from two X chromosomes. The gonosomal protein phosphatase 2 regulatory subunit B, beta (PPP2R3B) gene is located on the pseudoautosomal region (PAR) of the X chromosome in females and the Y chromosome in males. We observed that, despite its location on the PAR that predicts equal dosage across genders, PPP2R3B expression was lower in males than in females and was independently correlated with poor clinical outcome. PPP2R3B codes for the PR70 protein, a regulatory substrate-recognizing subunit of protein phosphatase 2A. PR70 decreased melanoma growth by negatively interfering with DNA replication and cell cycle progression through its role in stabilizing the cell division cycle 6 (CDC6)-chromatin licensing and DNA replication factor 1 (CDT1) interaction, which delays the firing of origins of DNA replication. Hence, PR70 functionally behaves as an X-linked tumor suppressor gene.</AbstractText><CopyrightInformation>Copyright © 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Kempen</LastName><ForeName>Léon C L</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Pathology, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redpath</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elchebly</LastName><ForeName>Mounib</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Kathleen Oros</ForeName><Initials>KO</Initials><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadakis</LastName><ForeName>Andreas I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Pathology, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilmott</LastName><ForeName>James S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Melanoma Institute Australia, Royal Prince Alfred Hospital, and University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scolyer</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Melanoma Institute Australia, Royal Prince Alfred Hospital, and University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edqvist</LastName><ForeName>Per-Henrik</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Immunology, Genetics and Pathology, and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontén</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Immunology, Genetics and Pathology, and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schadendorf</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Cancer Consortium (DKTK), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rijk</LastName><ForeName>Anke F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michiels</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Research in Epidemiology and Population Health (CESP), INSERM, UMR 1018, Université Paris-Sud, Kremlin-Bicetre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumay</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre de Recherche sur l'Inflammation, INSERM, UMR S 1149, Labex Inflamex, Université Paris-Diderot Sorbonne Paris-Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helbling-Leclerc</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CNRS, UMR 8200, Université Paris-Sud, Villejuif, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS UMR 8200, Universite Paris-Sud, Gustave Roussy, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dessen</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hématopoïèse normale et pathologique, INSERM UMR 1170, Université Paris-Sud, Gustave Roussy, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wouters</LastName><ForeName>Jasper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Computational Biology, VIB Center for the Biology of Disease, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stass</LastName><ForeName>Marguerite</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenwood</LastName><ForeName>Celia M T</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghanem</LastName><ForeName>Ghanem E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Oord</LastName><ForeName>Joost</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feunteun</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CNRS UMR 8200, Universite Paris-Sud, Gustave Roussy, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spatz</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, McGill University, Montreal, Quebec, Canada. alan.spatz@mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>01</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>08</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27974665</ArticleId><ArticleId IdType="pii">8/369/369ra177</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aai9188</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001411 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001411 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27974665
|texte= The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27974665" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |